Sincalide is owned by Maia Pharms Inc.

Sincalide contains Sincalide.

Sincalide has a total of 2 drug patents out of which 0 drug patents have expired.

Sincalide was authorised for market use on 22 November, 2022.

Sincalide is available in powder;intravenous dosage forms.

Sincalide can be used as accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract; stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis; stimulate gallbladder contraction. as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis, diagnosis of gall bladder disorders or other diagnostic imaging by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; diagnosis of pancreatic disorders by stimulating pancreatic secretion in combination with secretin prior to obtajning a duodenal aspirate for analysis; diagnostic imaging by accelerating the tran it ofa barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.

The generics of Sincalide are possible to be released after 20 April, 2038.